Global Pneumonia Therapeutics Market Is Driven by the Growing Prevalence of Pneumonia Across the Globe Coupled with Continuous R&D Efforts to Address the Same

Pneumonia is a prevalent form of an acute respiratory infection caused by fungi, bacteria, or viruses. Clinical manifestations can be as severe as painful breathing and oxygen deficiency due to limited intake with common symptoms such as chest pain, dry cough, and fever. In some instances, the disease can be as severe as fatal for patients. The pneumonia therapeutics market encapsulates products such as drugs—vaccines, and other therapeutic molecules that address clinical pneumonia treatment and management. The market is primarily driven by the growing prevalence of pneumonia across the globe. Further, a high mortality rate is associated with diseases, which fuels the demand for these market products immensely. The mortality is highest in the African and certain underdeveloped economies, which provides lucrative opportunity pockets for market leaders to penetrate these new markets. According to WHO, the estimated cost of diagnostics, treatment, and pneumonia management is around 109 million USD annually. Thus, low cost yet effective products from market players could help capitalize on these regions' unchartered market. Further, one of the major infection sources is a hospital-acquired infection where most patients develop serious complications that include renal failure, respiratory failure, and empyema due to severe worsening health conditions. Therefore, due to such severe complications, the demand for immediate management of pneumonia therapeutics drugs is expected to drive the market during the forecast period. Got questions about your regional growth of Pneumonia Therapeutics Market? Just drop us a line or call on +1 646 480 7505 Further, the rising number of clinical trials for vaccines and generic drugs and increasing funding for new product development to address disease management is anticipated to drive market growth. Moreover, the high numbers of regulatory approvals have seen the launch of several such products in the market. For instance, in September 2018, Pfizer received approval from the U.S. FDA for its 20-Valent Pneumococcal Conjugate Vaccine. This vaccine is found application in the prevention of pneumonia and invasive disease. Other major players in the market that include Merck, Mylan, Novartis, Sanofi, Abbott, Lupin, Elli Lilly and company, are also investing in significant sums to address these issues.     Key Highlights The global pneumonia therapeutics market was valued at USD 1700 million in 2019 and is expected to grow at 7.8% CAGR during the forecast period. By Drug class, Therapeutic Drugs account for the largest revenue share in the global market share. The online pharmacy segment is expected to witness a boost during the forecast period. The North American global market dominates the global market in terms of revenue. The Asia-Pacific market is expected to witness a steady growth during the forecast period. This is primarily due to the burden of pneumonia in the regional countries. Pneumonia Therapeutics Market: Segmentation By Drug Class Vaccines Therapeutic Drugs Antibacterial Drugs Antiviral Drugs Antifungal Drugs Others By Age Group Pediatric Adult Geriatric By Mode of Infection Hospital-acquired pneumonia (HAP) Community-acquired pneumonia (CAP) Ventilator-associated pneumonia (VAP) By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies By Region America Europe Asia-Pacific The Middle East and Africa " Crucial Insights The Report Provides:" * Known and Unknown Adjacencies Influencing the Growth of Market * Explorable Revenue Sources * Customer Behaviour Analysis * Target Partners * Customized Geographical Data Based on Customers as well as Competitors * Analysis of Market Size and CAGR between the Forecast Periods View Full Report Buy This Report Now